Profiling the efficacy of CR1 monoclonal antibody series against New World Arenaviruses
Antibody Therapeutics · 03.09.2026
DOI: 10.1093/abt/tbag046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 03.09.2026. Verfasst von Sharon Jan und 22 weiteren Autor:innen. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Energy’s National Nuclear Security Administration.
Abstract (Originalsprache)
Background
Junín virus (JUNV) is the causative agent of Argentine Hemorrhagic Fever (AHF) with the capacity for human-to-human transmission. AHF is endemic to Argentina and is prevented in at-risk populations with the regionally approved Candid#1 live attenuated vaccine (JUNV/C#1). However, there are barriers to US FDA (Federal Drug Administration) or EMA (European Medicines Agency) licensure of JUNV/C#1, and there are no approved post-exposure medical countermeasures (MCMs). The CR1-series of monoclonal antibodies (mAbs), isolated from JUNV/C#1 recipients by the Abraham lab (Clark et. al, 2018) have been proposed as MCMs for the treatment of AHF.
Methods
Several of these antibodies were evaluated here for potential cross-protection to other pathogenic New World Arenaviruses (NWAV) by binding, mutational scanning, and chimeric virus neutralization assay. Protective efficacy against challenge with authentic JUNV was determined by prophylactic administration in a guinea pig model of AHF.
Results
Although mAb cross-binding to the soluble receptor binding domain of the viral glycoprotein (sGP1) from multiple strains of JUNV, and the related hemorrhagic fever causing NWAV, Machupo was observed, these mAbs did not cross bind other NWAVs: Guanarito, Sabia, and Chapare. The Hartley outbred guinea pig model of AHF was used to demonstrate the protective efficacy of CR1-28 for the prevention of AHF-like disease.
Conclusions
This study provides the first proof-of-concept evidence for mAb prophylaxis of AHF. However, the results also demonstrated that CR1-10 is not protective as a monotherapy.
Förderung
- U.S. Department of Energy’s National Nuclear Security Administration
Zitieren
APA
Jan, S., Sumner, C. A., Sandoval, G. A., Won, S., Weinstock, L. D., Lara, A. L., Sinha, A., Shelby, M., Grzesiak, E., Goncalves, A., Silva, M., Engelhart, E., Rangarajan, S., Kerzic, M. C., Mitchell, C. A., Allmon, E. B., Goez-Gazi, Y., Dutton, J. W., Carrion, R., …, & Johnson, D. M. (2026). Profiling the efficacy of CR1 monoclonal antibody series against New World Arenaviruses. Antibody Therapeutics. https://doi.org/10.1093/abt/tbag046
Vancouver
Jan S, Sumner CA, Sandoval GA, Won S, Weinstock LD, Lara AL, et al. Profiling the efficacy of CR1 monoclonal antibody series against New World Arenaviruses. Antibody Therapeutics. 2026. doi:10.1093/abt/tbag046
BibTeX
@article{Jan2026,
author = {Jan, Sharon and Sumner, Christopher A and Sandoval, Grecia A and Won, Stephen and Weinstock, Laura D and Lara, Anna L and Sinha, Anupama and Shelby, Megan and Grzesiak, Emilia and Goncalves, Andre and Silva, Mary and Engelhart, Emily and Rangarajan, Sneha and Kerzic, Melissa C and Mitchell, Carter A and Allmon, Elizabeth B and Goez-Gazi, Yenny and Dutton, John W and Carrion, Ricardo and Desautels, Thomas and Alfson, Kendra J and Cirimotich, Chris M and Johnson, Dylan M},
title = {Profiling the efficacy of CR1 monoclonal antibody series against New World Arenaviruses},
journal = {Antibody Therapeutics},
year = {2026},
doi = {10.1093/abt/tbag046}
}
EUVIMED